DoW Breast Cancer, Clinical Research Extension Award | HT942526BCRPCREA

FY26 BCRP Clinical Research Extension Award (HT942526BCRPCREA) - FAQs

1) What is the FY26 BCRP Clinical Research Extension Award?

The FY26 Breast Cancer Research Program (BCRP) Clinical Research Extension Award is a U.S. Department of the Army (USAMRAA) discretionary grant opportunity that supports extension activities for existing breast cancer clinical studies. Its purpose is to strengthen the value of prior or ongoing clinical research by enabling extended data collection, longer-term participant follow-up, and deeper analysis of existing study data and samples.

2) What is the main goal of this award mechanism?

The main goal is to reduce the scientific and clinical knowledge that can be lost when a trial ends early, when follow-up is too short to capture meaningful outcomes, or when sample/data collection and analysis are incomplete. The award is intended to preserve and amplify the clinical insight already generated by a study foundation that exists today.

3) Is this opportunity meant to fund brand-new clinical trials?

No. This mechanism is described as focusing on getting more meaningful clinical insight from studies that have already enrolled patients or generated samples and datasets, rather than primarily funding brand-new trials.

4) What types of project activities are supported under this award?

Supported activities may include extending participant follow-up to capture long-term outcomes (such as survival, recurrence, toxicity, and quality-of-life outcomes), expanding or completing the collection of biospecimens or clinical data that were missing or limited, and conducting additional analyses that improve interpretation and clinical usefulness of the existing study results.

5) What outcomes does the program consider important to capture with extended follow-up?

The opportunity highlights clinically meaningful endpoints such as long-term survival, recurrence, toxicity, and quality-of-life outcomes, along with other endpoints that are clinically meaningful for breast cancer.

6) Does the program want more data collection just for its own sake?

No. The intent is explicitly described as not simply generating more data, but increasing the clinical relevance and utility of the existing or prior breast cancer clinical research effort.

7) What does "patient-centered impact" mean in this context?

The program emphasizes honoring and maximizing what participants have already contributed by ensuring their involvement leads to clearer conclusions, stronger evidence, and improved translational relevance. In other words, extension work should help translate participant contributions into results that matter for patients and clinical decision-making.

8) Do applications need to align with specific BCRP priorities?

Yes. Applications are expected to align with at least one of the FY26 BCRP overarching challenges, which serve as the programmatic priorities for that fiscal year.

9) What if a proposed project does not clearly address an FY26 BCRP overarching challenge?

If a project does not clearly address one of the challenges, the application must provide a strong justification for why an exception is warranted. Applicants should be prepared to explicitly connect the extension work and anticipated outcomes to BCRP priorities.

10) Are consumer advocates required to be part of the research team?

Yes. The research team must include at least two breast cancer consumer advocates. This requirement is intended to keep the project grounded in the needs and priorities of people affected by breast cancer and to formalize advocate involvement as part of the research team.

11) How many consumer advocates are required?

At least two breast cancer consumer advocates must be included on the research team.

12) Can the project be led by more than one Principal Investigator (PI)?

Yes. The award allows either a single PI structure or a two-PI partnering structure.

13) How does the two-PI Partnering PI Option work?

Under the Partnering PI Option, there is an Initiating PI and a Partnering PI. Only the Initiating PI submits the pre-application. At the full application stage, both PIs must submit their associated applications by the deadline.

14) What happens if both PI submissions are not received on time under the partnering option?

If the required Initiating and Partnering submissions are not both received by the deadline at the full application stage, the application can be administratively withdrawn. Teams using the partnering option should coordinate closely to avoid missed submission requirements.

15) What is the Funding Opportunity Number for this grant?

The Funding Opportunity Number is HT942526BCRPCREA.

16) What is the CFDA number for this opportunity?

The CFDA number listed is 12.420.

17) How is this opportunity categorized?

It is categorized as Science and Technology and other Research and Development.

18) Who is eligible to apply?

Eligibility is listed as unrestricted, indicating a wide range of applicant organizations may apply, subject to standard grant rules and any additional requirements stated in the full announcement.

19) How many awards does the sponsor expect to make?

The sponsor anticipates making approximately two awards.

20) What is the application closing date?

The original closing date is July 8, 2026.

21) What is the maximum award amount (ceiling) for this opportunity?

The award ceiling is not specified in the provided information. Applicants would need to consult the full funding announcement for the maximum allowable budget, period of performance, and any cost constraints or required justifications.

22) What should applicants do to confirm budget limits and project period details?

Because the ceiling and other budget details are not provided here, applicants should review the full funding announcement for the maximum allowable budget, period of performance, and any cost constraints or justification requirements.

23) What kind of project is considered a good fit for this opportunity?

A strong fit is a team that already has a clinical study foundation and can make a credible case that additional follow-up, improved data completeness, or enhanced analysis will materially change what clinicians, patients, and researchers can learn from that study.

24) What is the overall intent of the mechanism in plain terms?

It is a mechanism to recover, preserve, and amplify clinical knowledge from breast cancer clinical studies that might otherwise remain incomplete due to practical limitations in the original study design, execution, or duration.